AstraZeneca signs deal for oral obesity drug and lifts profit outlook
Anglo-Swedish drugmaker’s oncology and rare disease medication sales offset waning demand for Covid jabs
Source: FT.com - Drugs and Healthcare - Category: Pharmaceuticals Source Type: news
More News: AstraZeneca | Cancer & Oncology | Eating Disorders & Weight Management | Obesity | Pharmaceuticals | Rare Diseases | Sweden Health